StockWireNews
Major News Out Of The BSGM Camp Today Could Bring This Stock Wall Street Buzz In The Short-term
April 9th
Good Afternoon,
Today, BSGM released some major news about a subsidiary in regards to "positive data." Check it out:
Positive Data Generated by Biosig Subsidiary ViralClear on [...] Published in bioRxiv
Westport, CT, April 09, 2020 (GLOBE NEWSWIRE) -
- Vicromax shown to decrease viral production of CV by over 98%
- Article highlights recent work done in laboratory studies of CV with Vicromax(tm) at the Galveston Lational Laboratory at The University of Texas Medical Branch
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that an article titled “The IMPDH inhibitor merimepodib suppresses [...] replications” to bioRxiv, an online archive and distribution service for reprints in the life sciences. This manuscript is authored by Natalya Bukeryeva, Emily Mantlo, Rachel Sattler, Chen Huang, Slododan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear.
The article is the first public disclosure of pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after Vicromax was acquired by ViralClear, the work continues under contract with ViralClear.
“Oftentimes if an antiviral agent such as Vicromax decreases viral production by over 90% as is presented in this article, it will have meaningful activity in the clinic,” said Dr. Zeldis, ViralClear’s Executive Chair and founder. “More data will be submitted to peer review journals over the coming weeks and we are looking forward to submission of our IND to the FDA and advancing to human trails with this potential therapeutic."
Vicromax(tm), a broad-spectrum anti-viral candidate, demonstrated strong activity against CV in cell cultures in laboratory testing. The pharmaceutical is currently undergoing extensive pre-clinical testing. The Company intends to pursue development of this agent for the treatment of CV through FDA-approved clinical trials in Q2 2020.
Read The Full Article Here.
BioSig Technologies, Inc. (BSGM)
BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.
Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.
-----
More About BioSig Technologies, Inc.
From the company website:
BioSig: A Pioneer in Signal Processing Solutions
At BioSig, we're working to develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System.
We built BioSig to achieve this vision – with a strong commitment to research, a world-class leadership team, and a network of expert partners. We are now achieving important milestones as we prepare to enter the fast-growing electrophysiology market, but our aspirations reach even further: to lead one of the most innovative and most promising frontiers in healthcare.
Our Path from Research to Growth
Since our founding in 2009, BioSig has built an impressive scientific and business track record. In less than 10 years, we have developed a first-of-its-kind technology, attracted significant investment, conducted pre-clinical studies with centers of excellence, signed a 10-year strategic agreement with Mayo Clinic, and developed a robust IP strategy.
We are now poised to commercialize our first product: the PURE EP™ System. In 2018, we received FDA 510(k) clearance for PURE EP™, began market launch, and BioSig was uplisted to the NASDAQ national exchange. In 2019, we plan to begin first-in-human trials, introduce PURE EP™ to medical centers nationwide, collect our first revenues, and further develop our IP and R&D. Looking further ahead, we expect to publish trial results, grow internationally, and expand our product pipeline.
Tapping the Fast-Growing EP Market
Initially, we are targeting the $4.6Bn electrophysiology (EP) market, which is growing at more than 10% annually and expected to exceed $8.5Bn by 2024*. Ultimately, we hope to expand the applications of our technology to new disease areas and markets - helping to bring the promise of bioelectronic medicine to millions of patients worldwide.
Building for the Long Term
We are building BioSig for long-term impact and growth. This intent guides every decision we've made: from our culture and team to our financing and research. Our goal is nothing less than to transform the treatment of the most challenging diseases today.
To achieve this goal, we have created a culture that values the highest quality work, thorough research and scientific expertise, and deep collaboration with leaders in our field. Our exceptional culture and ambitious vision are already attracting high-powered new hires and partners for the next stage of our growth.
https://www.biosig.com/
-----
